Peptide Therapeutics Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation

Peptide Therapeutics Market Analysis | CMI


Read here the latest updates on the Peptide Therapeutics Market Analysis published by CMI team – PowerPoint PPT presentation

Number of Views:2
Date added: 30 September 2020
Slides: 16
Provided by: Shweta2707
Category: Other


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Peptide Therapeutics Market Analysis | CMI

  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Peptide Therapeutics Market, By Type (Branded
    Peptide, Generic Peptide), By Application
    (Cancer, Cardiovascular Disease, Metabolic
    Disease, Respiratory Disease, Infectious Disease,
    Others), By Route of Administration (Oral
    Administration, Parenteral Administration,
    Others), and By Region (North America, Latin
    America, Europe, Asia Pacific, Middle East
    Africa) - Size, Share, Outlook, and Opportunity
    Analysis, 2019 - 2027
  • The global peptide therapeutics market is
    estimated to account for US 23,319.3 Mn in terms
    of value and is expected to reach US 57,166.5 Mn
    by the end of 2027.

Global Peptide Therapeutics Market Drivers
  • Increasing prevalence of metabolic diseases and
    cardiovascular disorders (CVDs) is expected to
    boost growth of the global Peptide Therapeutics
    Market over the forecast period. For instance,
    according to American Heart Associations Heart
    Disease and Stroke Statistics 2018, around 92.1
    million adults in the U.S. are suffering from
    some form of CVD or the after-effects of stroke.
  • Moreover, increasing healthcare expenditure is
    also expected to aid in growth of the market. For
    instance, according to the Centers for Medicare
    Medicaid Services (CMS), health spending in the
    U.S. is projected to grow at an average rate of
    5.5 per year for 2018-27 and to reach nearly US
    6.0 trillion by 2027.

  • North America region held dominant position in
    the global peptide therapeutics market in 2018,
    accounting for 42.1 share in terms of value,
    followed by Europe.

Global Peptide Therapeutics Market Restraints
  • Poor chemical and physical stability and a short
    circulating plasma half-life of naturally
    occurring peptides are expected to hinder growth
    of the global peptide therapeutics market.
  • Moreover, presence of stringent safety
    regulations is also restraining the market
    growth. Pharmaceuticals products such as peptide
    therapeutics require better regulatory framework
    as these treat multiple pathological conditions
    by 2020, the regulatory framework is expected to
    be better.

Global Peptide Therapeutics Market Opportunities
  • RD of new peptides is expected to offer
    lucrative growth opportunities for players in the
    market. For instance, in December 2019, CohBar,
    Inc. announced new preclinical data that
    confirmed the therapeutic potential of a novel
    CohBar peptide in a preclinical model of
    Idiopathic Pulmonary Fibrosis (IPF).
  • Moreover, RD in microbiome research is also
    expected to boost growth of the peptide
    therapeutics market. In January 2020, researchers
    from The Chaim Sheba Medical Center, Israel,
    reported that high fructose consumption induced
    metabolic changes and dysbiosis in rats and that
    metabolic changes are probably independent of a
    specific microbiome profile.
  • Parenteral sub segment in the route of
    administration segment in global peptide
    therapeutics market was valued at US 16,416.8 Mn
    in 2018 and is expected to reach US 40,790.6 Mn
    by 2027 at a CAGR of 10.5 during the forecast

Market Trends/Key Takeaways
  • The market is witnessing increasing adoption of
    new platforms that develop next-generation
    protein or peptide therapeutics. For instance, in
    January 2020, Xenetic Biosciences, Inc. announced
    publication of the data from the completed Phase
    1/2 clinical study of SHP656 ("PSA-recombinant
    Factor VIII", "PSA-rFVIII") in the journal
    Haemophilia. The study used Xenetic's PolyXen
    technology a patent-protected platform
    technology for creating next-generation protein
    or peptide therapeutics.
  • The market is also witnessing increasing MA
    activities. For instance, in January 2020,
    Almirall, S.A. acquired Bioniz Therapeutics Inc.,
    a clinical stage biopharmaceutical company that
    develops first-in-class peptide treatments for
    immuno-inflammatory diseases.

  • U.S.
  • As per the FDC and PHS act of the U.S. FDA, CDER
    and CBER are responsible for certain part of
    therapeutic proteins
  • CDER now has regulatory role, which includes
    premarket review and continuing oversight of
    therapeutic peptides
  • 2012 As per FDA, peptides are defined as any
    alpha amino acid polymer with specific defined
    sequence that is 40 amino acids or less in size.
  • Since there are various peptide conjugate
    candidates that contain peptides in combination
    with small molecules, the regulatory aspect for
    peptide is still evolving
  • The FDA takes into account the history and
    manufacturing aspect of the candidate molecule to
    decide its regulatory pathway Example whether BLA
    would be submitted or NDA needs to be applied
  • All the non-clinical studies are carried out as
    per ICH-S6 guidelines

(No Transcript)
Global Peptide Therapeutics Market Competitive
  • Major players operating in the global peptide
    therapeutics market include, AstraZeneca plc.,
    Bachem Holding AG, CordenPharma International,
    Eli Lilly and Company, Ipsen S.A, Merck Co.,
    Inc., Novo Nordisk A/S, PolyPeptide Group, and
    Teva Pharmaceutical Industries Ltd.

Global Peptide Therapeutics Market Key
  • Major players in the market are focused on
    adopting collaboration strategies to expand their
    product portfolio. For instance, in October 2019,
    PolyPeptide Group collaborated with the Green
    Chemistry and Enabling Technologies Team of IBMM
    (Institut des Biomolécules Max Mousseron), for
    RD greener solutions to produce synthetic
  • Major players in the market are also focused on
    adopting MA strategies to expand their product
    portfolio. For instance, in July 2019, Xenetic
    Biosciences, Inc. completed acquisition of the
    novel CAR T (Chimeric Antigen Receptor T Cell)
    platform technology, called XCART, designed to
    use screening technique to identify peptide
    ligands that bind specifically to the unique
    B-cell receptor of malignant tumor cells.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//